| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Aug 22, 2023Broad strength across businesses and geographies results in mid-single digit revenue growth, driven by execution, innovation, and improved underlying fundamentals DUBLIN, Aug. 22, 2023...
Aug 23, 2022Revenue exceeds guidance, with known supply chain challenges impacting results; notable strength in Pacing, Cardiac Surgery, Core Spine in the U.S., and Diabetes in Europe DUBLIN, Aug. 23, 2022...
May 26, 2022Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns DUBLIN, May 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today...
-
Feb 22, 2022
Company advanced its pipeline, launched new products, won share, and delivered earnings growth despite COVID-19 impact on healthcare procedure volumes DUBLIN, Feb. 22, 2022 /PRNewswire/ --...
-
Jan 24, 2022Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration approval of its Intellis™ rechargeable neurostimulator and...
Jan 14, 2022DTM™ SCS endurance therapy enables long-lasting recharge-free performance on Vanta™ and 5-minute recharge on Intellis™ neurostimulators DUBLIN, Jan. 14, 2022 /PRNewswire/ -- Medtronic plc...
-
Jan 12, 2022
Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain DUBLIN, Jan. 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...
Nov 23, 2021Company continued to launch new products, win share, and deliver strong earnings growth; market procedure volumes impacted by COVID-19 resurgenceMedtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021. Key Highlights Revenue of $7.8 billion increased 3% reported...
Aug 24, 2021Strong Financial Performance on Continued Procedure Volume Recovery and Share Gains from New Product LaunchesMedtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021. Key Highlights Revenue of $8.0 Billion Increased 23% Reported and...
Jun 10, 2021Vanta™ Implantable Neurostimulator Offers Up to 11 Year Battery Life and Personalized Pain ReliefMedtronic plc (NYSE: MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™, a high performance recharge-free...
-
May 27, 2021- Q4 Revenue of $8.2 Billion Increased 37% Reported and 32% Organic
Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2021, which ended April 30, 2021. The company reported fourth quarter worldwide revenue of $8.188...
Mar 17, 2021Revised Commercial Labeling to Reflect Outcomes of a Randomized Controlled Trial Demonstrating Superiority of DTM™ Spinal Cord Stimulation (SCS) Compared to Conventional SCS for the Treatment of Chronic Intractable Back PainMedtronic plc (NYSE: MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised commercial labeling for the Intellis™...
Oct 20, 2020Study Reports 84% Back Pain Responder Rate and 69% Profound Responder Rate at 12 Months(1)Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced statistically significant 12-month results from a large, multicenter randomized controlled trial (RCT) that...
-
Oct 14, 2020
Company Raises Revenue Growth Outlook Highlights Deep and Broad Pipeline and Technology Platforms DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical...
-
Jan 21, 2020At Three-Months, 80% of Patients Treated with DTM SCS Reported Back Pain Relief of at Least 50%; 63% Reported Profound Back Pain Relief of 80% or Greater1
DUBLIN, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced three-month results from a large, multicenter randomized controlled trial (RCT) showing statistically significant...
-
Jan 8, 2020Randomized Control Trial Results to be Presented at NANS Jan. 23-26 in Las Vegas; New, Proprietary Differential Target Multiplexed (DTM) Therapy Available on Medtronic Intellis Spinal Cord Stimulation Platform
DUBLIN, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) announced it has acquired Stimgenics, LLC, a privately-held company based in Bloomington, Illinois, that has pioneered a novel...
-
May 23, 2019Q4 Revenue of $8.1 Billion, Flat as Reported and Grew 3.6% Organic
DUBLIN - May 23, 2019 - Medtronic plc (NYSE:MDT) today announced financial results for its fiscal year and fourth quarter 2019, which ended April 26, 2019. Medtronic's fiscal year 2019 revenue of...
-
May 7, 2019To Assess the Potential of Non-Opioid Treatment Options for Chronic Pain, Study Evaluates Pain Relief, Patient Function and Satisfaction
DUBLIN and LAS VEGAS - May 7, 2019 - Medtronic plc (NYSE:MDT) today announced primary endpoint (3-month) results of the Vectors Post Market Clinical Study that demonstrated effective pain relief...
-
Feb 19, 2019Revenue of $7.5 Billion Increased 2.4% Reported; Increased 4.4% Organic
DUBLIN - February 19, 2019 - Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2019, which ended January 25, 2019. The company reported third quarter...
-
Nov 20, 2018Revenue of $7.5 Billion Increased 6.1% Reported; Increased 7.5% Organic
DUBLIN - November 20, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2019, which ended October 26, 2018. The company reported second...
-
Aug 21, 2018(GLOBE NEWSWIRE via COMTEX) --- Revenue of $7.4 Billion Decreased 0.1% Reported; Increased 6.8% Organic
DUBLIN - August 21, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2019, which ended July 27, 2018. The company reported first quarter...
-
May 24, 2018Q4 Revenue of $8.1 Billion Grew 2.9% Reported and 6.5% Organic
DUBLIN - May 24, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2018, which ended April 27, 2018. The company reported fourth quarter...
-
Feb 20, 2018Revenue of $7.4 Billion Increased 1% as Reported; 7% at Comparable, Constant Currency
DUBLIN - February 20, 2108 - Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2018, which ended January 26, 2018. The company reported third quarter...
-
Jan 9, 2018As More Physicians Seek Non-Opioid Treatment Options, the Vectors Study Will Further Advance Understanding of New Approaches to Optimal Spinal Cord Stimulation Treatment
DUBLIN - January 9, 2018 - Medtronic plc (NYSE:MDT) today announced the first patient enrolled in the Vectors Post Market Clinical Study. The study will follow patients with chronic intractable...
-
Nov 6, 2017New Neurostimulation System Is a Non-Opioid Alternative for Chronic Pain and Offers Personalized Pain Relief and Advanced Activity Tracking
DUBLIN - November 6, 2017 - Medtronic plc (NYSE:MDT) today announced that it received CE (Conformité Européenne) Mark for the Intellis(TM) platform for both Spinal Cord Stimulation (SCS) and...